Compounds and their use as positive AMPA receptor modulators

A compound represented by Formula (II):

• wherein
• R2 represents hydrogen;
• and
• R3 represents hydrogen, cycloalkyl, or unsubstituted alkyl;
• or a carbocyclic 7- to 12-membered ring, which carbocyclic ring is optionally substituted with halogen, alkyl, hydroxy or alkoxy;
• and
• R4 represents hydrogen or alkyl;
• and
• R5 represents hydrogen, alkyl, or phenyl;
• and
• R6 represents hydrogen, halogen, alkyl, or alkoxy;
• phenyl optionally substituted with alkoxy;
• and
• R7 represents
• alkyl, cyano, or hydroxyalkyl;
• or
• a group selected from —NHSO2—R17, —SO—R17, —SO2—NR17R18, —CR′═NOR″, or —CO2—R17, wherein R′ and R″ independently represents hydrogen and/or alkyl;
• and R17 and R18 independently represents alkyl and/or phenyl;
• or R17 and R18 together with the nitrogen to which they are attached forms a pyrrolidine, piperidine, piperazine, morpholine, or tetrahydropyridine group, which ring structure is optionally substituted with alkyl or —SO2-alkyl;
• a pyridyl, pyrimidyl, triazolyl, furyl, thienyl, oxadiazolyl, or imidazolyl group, optionally substituted with alkyl or phenyl;
• or
• phenyl, optionally substituted with one or two substituents selected from the group consisting of hydroxy, alkoxy, halogen, haloalkyl, —NHCO-alkyl, nitro, and —SO2—NR17R18, wherein R17 and R18 represent alkyl;
• and
• R8 represents hydrogen;
• provided however,
• if R5 is alkyl and/or R6 is halogen or alkyl or alkoxy and/or R7 is alkyl, then one or more of the remainder of R5, R6, or R7 is/are not also alkyl, and then one or more of the remainder of R5, R6, or R8 is/are not hydrogen.